絞り込み

16546

広告

Acute myeloid leukemia induces pro-tumoral p16INK4a driven senescence in the bone marrow microenvironment.

著者 Abdul-Aziz AM , Sun Y , Hellmich C , Marlein CR , Mistry J , Forde E , Piddock RE , Shafat MS , Morfakis A , Mehta T , Di Palma F , Macaulay I , Ingham CJ , Haestier A , Collins A , Campisi J , Bowles KM , Rushworth SA
Blood.2018 Nov 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

Miscellaneous

Acute myeloid leukemia (AML) is an age-related disease that is highly dependent on the bone marrow microenvironment. With increasing age, tissues accumulate senescent cells, characterized by an irreversible arrest of cell proliferation and the secretion of a set of pro-inflammatory cytokines, chemokines and growth factors, collectively known as the senescence-associated secretory phenotype (SASP). Here, we report that AML blasts induce a senescent phenotype in the stromal cells within the bone marrow microenvironment. We report that the bone marrow stromal cell senescence is driven by p16INK4a expression. The p16INK4a-expressing senescent stromal cells then feedback to promote AML blast survival and proliferation via the SASP. Importantly, selective elimination of p16INK4a-positive senescent bone marrow stromal cells improved the survival of mice with leukemia. Next, we find that the leukemia-driven senescent tumor microenvironment is caused by AML induced NOX2-derived superoxide. Finally, using the p16-3MR mouse model we show that by targeting NOX2 we reduced bone marrow stromal cell senescence and consequently reduced AML proliferation. Together, these data identify leukemia generated NOX2 derived superoxide as a driver of pro-tumoral p16INK4a-dependent senescence in bone marrow stromal cells. Our findings reveal the importance of a senescent microenvironment for the pathophysiology of leukemia. These data now open the door to investigate drugs which specifically target the 'benign' senescent cells that surround and support AML.
PMID: 30401703 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード